A Risk-Adapted Strategy of Adjuvant Paclitaxel/Carboplatin in Early-Stage Ovarian Cancer: Time-Dependent Effect of 4 versus 6 Cycles on Outcome

Aristotle Bamias; Christina Bamia; Alexandra Karadimou; Nikolaos Soupos; Flora Zagouri; Alexandros Rodolakis; Dimitrios Haidopoulos; George Vlahos; N. Thomakos; A. Antsaklis; Meletios A Dimopoulos

doi:10.1159/000334230

Shared by

Meletios A Dimopoulos

A Risk-Adapted Strategy of Adjuvant Paclitaxel/Carboplatin in Early-Stage Ovarian Cancer: Time-Dependent Effect of 4 versus 6 Cycles on Outcome

Article 2011 en

Authors

AB
Aristotle Bamias
CB
Christina Bamia
AK
Alexandra Karadimou

Abstract

1 min read

Six cycles of chemotherapy reduced the risk of relapse within 2 years, but the benefit from two additional cycles beyond this time is questionable.

Related publications

Article2006

Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group

Aristotle Bamias, Christos Papadimitriou, Eleni Efstathiou, Alexandros Rodolakis, Georgios Vlahos, Zannis Voulgaris, George Bozas, George Fountzilas, Gerasimos Aravantinos, Evagelia Razis, Dimitra Gika, Meletios A Dimopoulos

Article2013

Two cycles of carboplatin as adjuvant therapy in stage I seminoma: 8-year experience by the Hellenic Co-operative Oncology Group (HECOG).

Konstantinos Koutsoukos, Michalis Liontos, Maria Lykka, Georgios Rigakos, Anna Andreadou, Eleni Efstathiou, Αngelos Koutras, Athanasios Papatsoris, Michael Chrisofos, Konstantinos Stravodimos, Ioanis Adamakis, Christos Alamanis, Vasilios Karavasilis, Thomas Makatsoris, Eleni Galani, G. Klouvas, P. Kosmidis, George Fountzilas, Meletios A Dimopoulos, Aristotelis Bamias

Article2003

Two cycles of carboplatin-based adjuvant chemotherapy for high-risk clinical stage I and stage IM non-seminomatous germ cell tumours of the testis: a HECOG trial.

Dimitrios Pectasides, Dimosthenis Skarlos, Meletios A Dimopoulos, Dimitrios Farmakis, Melina Pectasides, George Fountzilas, Gerasimos Aravantinos

Article2001

Dose-Dense Sequential Adjuvant Chemotherapy with Epirubicin, Paclitaxel and CMF in High-Risk Breast Cancer

George Fountzilas, C. Papadimitriou, Gerasimos Aravantinos, C. Nicolaides, G. Stathopoulos, Dimitrios Bafaloukos, Haralabos P. Kalofonos, T. Ekonomopoulos, D. Skarlos, Nicholas Pavlidis, Meletios A Dimopoulos

Article2019

Phase III KEYNOTE-716 study: Adjuvant therapy with pembrolizumab versus placebo in resected high-risk stage II melanoma.

Jason J. Luke, Paolo A. Ascierto, Matteo S. Carlino, Alexander Eggermont, Jean‐Jacques Grob, Axel Hauschild, John M. Kirkwood, Georgina V. Long, Peter Mohr, Caroline Robert, Jeffrey E. Gershenwald, Andrew Poklepovic, Merrick I. Ross, Richard A Scolyer, Charles H. Yoon, James R. Anderson, Sama Ahsan, Nageatte Ibrahim, Vernon K. Sondak

A Risk-Adapted Strategy of Adjuvant Paclitaxel/Carboplatin in Early-Stage Ovarian Cancer: Time-Dependent Effect of 4 versus 6 Cycles on Outcome

Abstract

Discussion(0)

Related publications

Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group

Two cycles of carboplatin as adjuvant therapy in stage I seminoma: 8-year experience by the Hellenic Co-operative Oncology Group (HECOG).

Two cycles of carboplatin-based adjuvant chemotherapy for high-risk clinical stage I and stage IM non-seminomatous germ cell tumours of the testis: a HECOG trial.

Dose-Dense Sequential Adjuvant Chemotherapy with Epirubicin, Paclitaxel and CMF in High-Risk Breast Cancer

Phase III KEYNOTE-716 study: Adjuvant therapy with pembrolizumab versus placebo in resected high-risk stage II melanoma.